Is Exact Sciences Corporation (EXAS) a Buy, Sell, or Hold?
NASDAQ : EXAS
Exact Sciences Corporation — News
$104.91 USD
$0 (0.0%)
- Volume
- 21.56M
- Average Volume
- 2.53M
- Market Capitalization
- $20.03B
- P/E Ratio
- -95.69
- Dividend Yield
- 0.00%
- Price Target
- $105.00
- Year High
- $104.98
- Year Low
- $38.81
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.23
| Source | Headline |
|---|---|
|
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
Abbott Laboratories NYSE: ABT gave the market what it wanted in its Q2 earnings report, affirming that the Exact Sciences acquisition was a good one. The critical takeaways are that comp growth is solid, the Exact Sciences business has traction, and the near-term margin impairment the acquisition brought is less than expected. marketbeat.com - 2026-07-16 13:45:22 |
|
Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering
Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution. seekingalpha.com - 2026-07-03 16:00:00 |
